Previous 10 |
Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.46. More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Achieved Alignment with U.S. Food and Drug Administration (FDA) on Phase 3 URIROX TM Program and Accelerated Approval Strategy for Reloxaliase -- -- Phase 3 URIROX-1 and URIROX-2 Trials Ongoing; URIROX-1 Topline Data Expected in Second Half of 2019 -- -- Louis Brenner, M.D. Ap...
NEWTON, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...
Investment Thesis: Allena Pharmaceuticals ( ALNA ) is a clinical-stage biotech company which currently specializes in treating hyperoxaluria and hyperuricemia. We have previously suggested that the risks to the initiation of the Phase III clinical trial were too high for investment and had...
News, Short Squeeze, Breakout and More Instantly...
Allena Pharmaceuticals Inc. Company Name:
ALNA Stock Symbol:
NASDAQ Market:
Allena Pharmaceuticals Inc. Website:
Buying Penny Stocks on July 29th? Here’s What You Need to Know If you’re looking for the best penny stocks to buy right now, there are hundreds of options to choose from. As a result, it all comes down to finding the best penny stocks that fit your trading strateg...
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme the...
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...